Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Saggu, G.; Stroopinsky, D.; Dudek, A. Z.; Olszanski, A. J.; Juric, D.; Dowlati, A.; Vaishampayan, U.; Assad, H.; Rodón, J.; Gibbs, J.; Green, J.; Du, Z.; Rudicell, R.; Kannan, K.; Gharavi, R.; Gomez-Pinillos, A.; Fram, R. J.; Berger, A.; Sachsenmeier, K.; Kasar, S.

Published in

Elsevier, European Journal of Cancer, (174), p. S125-S126, 2022

DOI: 10.1016/s0959-8049(22)01134-0

Tools

Export citation

Search in Google Scholar

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study

Journal article published in 2022 by G. Saggu, D. Stroopinsky, A. Z. Dudek, A. J. Olszanski, D. Juric, A. Dowlati, U. Vaishampayan, H. Assad, J. Rodón

, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study